Nonendoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma in At-Risk Veterans.
Katarina B Greer, Andrew E Blum, Ashley L Faulx...
https://pubmed.ncbi.nlm.nih.gov/38989889/Actively Recruiting
Led by Louis Stokes VA Medical Center · Updated on 2025-06-05
400
Participants Needed
1
Research Sites
52 weeks
Total Duration
This research focuses on veterans at higher risk for esophageal adenocarcinoma EAC and its precursor, Barretts esophagus BE, due to factors like age, gender, obesity, smoking, and family history. Current guidelines recommend screening only for those with reflux symptoms, but many patients who develop EAC do not report such symptoms. This study evaluates a non-endoscopic screening method to detect BE in veterans without chronic reflux but with multiple risk factors, aiming to improve detection rates and reduce the need for costly endoscopy. Participants will undergo a non-endoscopic test called Esocheck, which collects esophageal tissue samples analyzed by the Esoguard assay for specific biomarkers linked to BE. Those eligible have no history of GERD and have at least three risk factors such as white race, male gender, obesity, smoking history, or family history of BE or EAC. After the Esocheck test, all participants will be offered a standard upper endoscopy EGD on the same day to confirm findings and provide diagnostic comparison. During the study, participants will provide informed consent and complete both the Esocheck screening and upper endoscopy. Researchers will analyze tissue samples for biomarker presence and compare results with endoscopy findings to assess sensitivity and specificity. They will also track acceptance rates and reasons for refusing screening. The primary outcome is the confirmation of BE or EAC diagnosis within 10 to 30 days. The study plans to enroll 400 veterans aged 40 to 85 without prior endoscopy and monitor results to improve future screening recommendations.
CONDITIONS
Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic Reflux
K
Katarina B. Greer, MD/MS
L
Lauren H. Hricik, BA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Louis Stokes VA Medical Center
Lead Sponsor
United States Department of Defense
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Nonendoscopic screening (Esocheck + Esoguard) | Standard diagnostic endoscopy (EGD + biopsy) |
|---|---|---|
| What it is | A swallowed encapsulated balloon device (EsoCheck) collects esophageal cells for analysis by a DNA methylation assay (EsoGuard) | Standard upper endoscopy with biopsy and histologic confirmation of Barrett’s esophagus or cancer |
| Role in trial | Investigational diagnostic test under evaluation alongside EGD | Reference standard used to confirm diagnosis in all participants |
| Primary use | Screen for Barrett’s esophagus and esophageal adenocarcinoma in at‑risk veterans without chronic reflux | Confirm diagnosis of Barrett’s esophagus or esophageal adenocarcinoma |
| How it is performed | Participant swallows an encapsulated balloon that collects esophageal cells for DNA methylation assay | Gastroenterologist performs upper endoscopy and obtains tissue biopsy for histology |
| Evidence status | Test accuracy being evaluated—comparison pending study results | Accepted diagnostic accuracy established in clinical practice |
| Important risks | Not yet established pending study safety results | Known procedural risks such as sedation effects, bleeding, perforation |
| Important limitations | Validation pending; sensitivity and specificity results not yet available in veterans without reflux | Invasive, requires sedation and specialist, less accessible for population screening |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Same day
Participants complete two diagnostic tests: a non-endoscopic Esocheck/Esoguard assay and an upper endoscopy performed on the same day to detect Barrett's esophagus or esophageal adenocarcinoma.
1 visit (in-person)
Duration - 10 to 30 days
Participants receive follow-up as diagnostic results are finalized and reviewed within 10 to 30 days after testing.
Follow-up contact to communicate results
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Katarina B Greer, Andrew E Blum, Ashley L Faulx...
https://pubmed.ncbi.nlm.nih.gov/38989889/Louis Stokes VA Medical Center
Lead Sponsor
United States Department of Defense
Collaborating Sponsor